Brenipatide

updated

Brenipatide (LY3537031) is an investigational Lilly injection, a modified 39-amino-acid peptide that activates both GIP and GLP-1 receptors, with no FDA approval. It is being studied in obesity and in addiction, psychiatric, respiratory and gut conditions. None of its 18 registered studies has posted results, so there is no public figure for weight loss, any other benefit or side effects; three completed phase 1 studies show only that they finished. Graded C for a defined molecule in a large human program whose outcomes remain unknown.

Dual GIP and GLP-1 receptor agonist peptide

  • Modified 39-amino-acid peptide
  • Also indexed as LY3537031
  • Studied mainly by subcutaneous injection
  • No posted results in the cited trial records

What is brenipatide, and why do some records say LY3537031?

Brenipatide is the international nonproprietary name for Lilly's LY3537031. WHO describes it as a modified 39-amino-acid agonist at both the GIP and GLP-1 receptors. ClinicalTrials.gov records under either name belong to the same development program.

Five earlier ClinicalTrials.gov records use LY3537031 without the brenipatide name. Thirteen newer records are indexed under brenipatide and also include the code.

source: WHO INN · identity and receptor class, World Health Organization, WHO Drug Information, 2025

source: ClinicalTrials.gov · 18 deduplicated records, ClinicalTrials.gov searches of the intervention field for LY3537031 and for brenipatide, run on 8 September 2026.

Is brenipatide an approved medicine?

The cited FDA records list no approval or prescribing label for brenipatide or LY3537031. It remains an investigational drug used in registered studies.

A WHO name, a ClinicalTrials.gov entry, and a phase 3 designation describe development status. They do not authorize a drug for sale.

source: FDA records · no approved entry, Drugs@FDA and FDA label records

What does the current trial registry actually show?

The cited ClinicalTrials.gov records list 18 studies under the exact LY3537031 intervention name: 6 phase 1, 8 phase 2, and 4 phase 3. Three were completed, two were active but not recruiting, eleven were recruiting, and two were not yet recruiting. None of the 18 cited trial records included posted results.

ClinicalTrials.gov status
Registry stateRecordsMeaning
Completed3The registered study ended; no result was posted
Active, not recruiting2Follow-up or study activity may continue
Recruiting11Enrollment was open in the registry
Not yet recruiting2The study was planned, without an outcome

Counts deduplicate the brenipatide and LY3537031 names by NCT identifier.

source: ClinicalTrials.gov · 18 deduplicated records

Why does one drug appear in so many unrelated programs?

The registered program tests separate hypotheses in obesity, substance-use disorders, psychiatric disorders, asthma, chronic obstructive pulmonary disease, and irritable bowel syndrome. Results in one population cannot answer whether the drug works in another.

Program map, grouped by the registered population
Program areaRegistered studies
Phase 1 and pharmacologyHealthy volunteers; overweight or obesity; hepatic impairment; renal impairment; absorption and bioavailability
Substance useTwo alcohol-use phase 3 trials; phase 2 smoking-relapse and opioid-use trials
PsychiatryBipolar disorder and schizophrenia phase 2; two major-depression phase 3 trials
RespiratoryAsthma and COPD phase 2
GastrointestinalIBS with diarrhea and IBS with constipation phase 2

The cited trial records contain no posted results.

source: ClinicalTrials.gov · 18 deduplicated records

Do the three completed phase 1 studies establish a safety profile?

The three completed records cover an early healthy-participant study, a renal-impairment pharmacokinetic study, and an absorption study. None posts adverse-event results, exposure tables, or a general contraindication list.

Completed is an administrative study status. Without posted results, it does not show how often adverse events occurred, whether any serious event was related to treatment, or which dose was tolerated.

source: ClinicalTrials.gov · 18 deduplicated records

Has brenipatide shown weight loss in people?

Two phase 1 records include participants with overweight or obesity, but neither provides a public brenipatide-specific weight-loss result. Registry status and enrollment alone cannot supply an efficacy estimate.

The current obesity study is active but not recruiting, has an estimated enrollment of 150, and has no posted results. It cannot support a percentage weight-loss claim or comparison with another drug.

source: NCT07476118 · obesity phase 1, ClinicalTrials.gov, NCT07476118

source: ClinicalTrials.gov · 18 deduplicated records

Does dual GIP and GLP-1 receptor agonism predict the clinical result?

Dual GIP and GLP-1 receptor activity identifies the drug's intended targets. It does not predict the size or direction of its effects in obesity, addiction, psychiatric, respiratory, or gastrointestinal trials.

Results from another dual agonist cannot be copied to brenipatide. Sequence, exposure, receptor activity, dose schedule, population, and endpoint all matter.

source: WHO INN · identity and receptor class

source: ClinicalTrials.gov · 18 deduplicated records

What can be said about dosing, interactions, and adverse effects?

There is no public prescribing label or posted brenipatide adverse-event dataset. The cited records do not establish a routine dose, titration schedule, missed-dose rule, contraindication list, pregnancy guidance, or interaction profile.

source: ClinicalTrials.gov · 18 deduplicated records

source: FDA records · no approved entry

Studies and sources

WHO INN · identity and receptor class

WHO nomenclature document

World Health Organization, WHO Drug Information, 2025

The INN entry names brenipatide and classifies it as a GIP and GLP-1 receptor agonist. Its chemical description contains 39 amino-acid residues with a modified side chain.

  • The INN confirms identity and intended pharmacology; it contains no clinical efficacy result.
Participants / model
Drug nomenclature record
Treatment
Brenipatide
Follow-up
Proposed INN list published 2025
Study design
International nonproprietary name document

An INN is a standardized name, not a drug approval.

Read the original source
ClinicalTrials.gov · 18 deduplicated records

Registry record set

ClinicalTrials.gov searches of the intervention field for LY3537031 and for brenipatide, run on 8 September 2026.

ClinicalTrials.gov listed 18 unique NCT records under LY3537031 and a 13-record subset under brenipatide. Phase counts were 6 phase 1, 8 phase 2, and 4 phase 3. Three were completed, two active not recruiting, eleven recruiting, and two not yet recruiting. None had posted results.

  • Counts represent unique NCT identifiers across both aliases.
  • Five records use only the development code, so the brenipatide name covers 13 of 18 records.
Participants / model
All ClinicalTrials.gov records indexed to the exact intervention aliases
Treatment
Brenipatide or LY3537031
Study design
Exact-intervention registry records grouped by NCT identifier
Funding
Study records list Eli Lilly and Company as sponsor

Registry status, phase, and enrollment are not efficacy or safety outcomes.

NCT07476118 · obesity phase 1

Clinical trial registry record

ClinicalTrials.gov, NCT07476118

The phase 1 subcutaneous study lists 150 estimated participants, active but not recruiting status, and no posted results.

Participants / model
Healthy adults with overweight or obesity
Treatment
Subcutaneous brenipatide or placebo under a research protocol
Follow-up
Estimated completion February 2027 in the cited record
Study design
Randomized phase 1 study
Funding
Eli Lilly and Company

The registry gives no public weight-loss estimate.

Read the original source

Why is Brenipatide in C tier?

C tier recognizes a defined molecule and 18 registered human studies. None of those records had posted results, so efficacy, adverse-event rates, contraindications, interactions, and routine dosing remain unknown.

how tiers are graded: methodology · every cited source · about reptides.

Research reference, not medical advice. Entries distinguish product labels, study doses and reported protocols. Check the linked source for the product, route and population.